Literature DB >> 23153053

Gonadotropin releasing hormone agonist and levonorgestrel-intrauterine device followed by in vitro fertilization program as management strategy for an infertile endometrial cancer patient: a case report.

Giuseppe Nucera1, Vincenzo Dario Mandato, Maria Carolina Gelli, Stefano Palomba, Giovanni Battista La Sala.   

Abstract

BACKGROUND: A progressive delay in the age of first conception results in an increased frequency of endometrial cancer patients in reproductive age and desiring childbearing. CASE: A 38-year-old infertile woman with stage I endometrioid adenocarcinoma was treated with gonadotropin releasing hormone agonist (GnRHa) and levonorgestrel-releasing intrauterine device (LNG-IUD). After disease remission, she underwent a controlled ovarian stimulation for standard in vitro fertilization (IVF) program and had a pregnancy delivering a healthy male baby. Total laparoscopic hysterectomy with bilateral salpingo-oophorectomy was performed four months after delivery. The patient is free of disease after 3-year follow-up.
CONCLUSION: GnRHa plus LNG-IUD followed by IVF program is a safe and effective fertility-sparing strategy to manage infertile patients with stage I endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153053     DOI: 10.3109/09513590.2012.738726

Source DB:  PubMed          Journal:  Gynecol Endocrinol        ISSN: 0951-3590            Impact factor:   2.260


  2 in total

Review 1.  Should Endometrial Cancer Treatment Be Centralized?

Authors:  Vincenzo Dario Mandato; Andrea Palicelli; Federica Torricelli; Valentina Mastrofilippo; Chiara Leone; Vittoria Dicarlo; Alessandro Tafuni; Giacomo Santandrea; Gianluca Annunziata; Matteo Generali; Debora Pirillo; Gino Ciarlini; Lorenzo Aguzzoli
Journal:  Biology (Basel)       Date:  2022-05-18

2.  Conservative therapy with metformin plus megestrol acetate for endometrial atypical hyperplasia.

Authors:  Weiwei Shan; Chao Wang; Zhenbo Zhang; Chao Gu; Chengcheng Ning; Xuezhen Luo; Qiongjie Zhou; Xiaojun Chen
Journal:  J Gynecol Oncol       Date:  2014-07-03       Impact factor: 4.401

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.